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Abstract: We tested the hypothesis that large areas of small hard drusen (diameter <63 µm)
and intermediate drusen (diameter 63–124 µm) are associated with the incidence of
age-related macular degeneration (AMD). Eyes of 3344 older adults with at least two
consecutive visits spaced five years apart over a 20-year period were included. A 6-level
severity scale, including no drusen, four levels of increasing area (from minimal
(<2596 µm²) to large (>9086 µm²)) of only small hard drusen, and intermediate drusen,
was used. The five-year incidence of AMD was 3% in eyes at the start of the interval with
no, minimal, small, and moderate areas of only small drusen and 5% and 25% for eyes
with large area of only small drusen and intermediate drusen, respectively. Compared to
eyes with a moderate area of small drusen, the odds ratio (OR) of developing AMD in eyes
with a large area of only small drusen was 1.8 (p < 0.001). Compared to eyes with large
area of only small drusen, eyes with intermediate drusen had an OR of 5.5 (p < 0.001) of

J. Clin. Med. 2015, 4

426

developing AMD. Our results are consistent with our hypothesis that large areas of only
small drusen are associated with the incidence of AMD.
Keywords: age-related macular degeneration; epidemiology; genetic risk; incidence;
retinal drusen; risk factors; size and area

1. Introduction
Age-related macular degeneration (AMD) is a complex chronic disease affecting multiple layers of
the retina. Histologically, its earliest subclinical stages have been defined by the presence of
age-related thickening of Bruch membrane with calcifications and basal laminar deposits prior to the
appearance of hard and soft drusen in the macula as detected by ophthalmoscopy [1]. Clinically, its
earliest stages are often defined by the presence of large soft drusen (≥125 µm in diameter) [2,3].
Progression of AMD involves the appearance of increasing numbers of large soft distinct and indistinct
drusen that may become confluent, as well as the development of pigmentary abnormalities
(depigmentation and increased retinal pigment) of the retinal pigment epithelium (RPE) in the macula.
Progression rates vary, with some eyes remaining in early stages of the disease over long periods of
time while others progress more rapidly to the late stages of the disease, geographic atrophy and
neovascular AMD. Reduction in choroidal perfusion and retinal tissue oxygenation levels, increased
systemic inflammation, presence of atherosclerosis, and elastic tissue degeneration have been
hypothesized to be involved in the pathogenesis of AMD [3,4]. Genes associated with the alternative
complement system, lipid metabolism, atherosclerosis, and other pathways have been found to be
associated with the development of late AMD [5,6].
Labeling an eye as having early AMD has been based on empirical evidence from epidemiological
studies (e.g., the Beaver Dam Eye Study, the Rotterdam Study, the Blue Mountains Eye Study),
clinical trials, such as the Age-Related Eye Disease Study (AREDS) and observations of clinical
cohorts [2,3,7–12]. In those studies, the presence of large drusen (≥125 µm in diameter) in one or both
eyes increased the risk of developing signs of late AMD [2,3,11]. In the AREDS, the presence of
intermediate drusen (between 63 and 124 µm in diameter) in both eyes was also associated with a
small but significant increase in risk of developing late AMD [2,11]. Presence of a few small hard
drusen is common and is not thought to be an early stage of AMD [13,14]. Eyes with a larger area of
only small hard drusen (>9086 µm2) compared with eyes with a smaller drusen area (<2596 µm²)
involving the macula have been found to be associated with increased age-adjusted 15-year cumulative
incidence of soft indistinct drusen (16.3% vs. 4.7%) and pigmentary abnormalities (10.6% vs. 2.7%) [7].
These findings suggested that a larger area of small hard drusen in the absence of larger soft drusen or
other retinal AMD lesions in an eye might be an even earlier clinical stage of AMD than that which is
currently defined by the presence of larger drusen.
We hypothesized that larger areas of only small hard drusen and the presence of intermediate drusen
were related to the incidence of AMD. We also hypothesized that age, sex, and two specific
single-nucleotide polymorphisms (SNPs), one in the complement factor H region (CFH Y402H
rs1061170) on chromosome 1 and the other in the age-related maculopathy susceptibility 2 region
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(ARMS2 A69S rs10490924) on chromosome 10, were related to the incidence of increasing areas of
small hard drusen and to intermediate drusen. Longitudinal data over a 20-year period from the Beaver
Dam Eye Study were used in the analyses.
2. Experimental Section
2.1. Study Population
Identification and descriptions of the population in the Beaver Dam Eye Study have appeared in
previous reports [15–20]. In brief, a private census identified 5924 persons living in the city and
township of Beaver Dam, Wisconsin aged 43–86 years, of which 4926 participated in the baseline
examination in 1988–1990 and in up to four follow-up examinations in 1993–1995, 1998–2000,
2003–2005 and 2008–2010. Over 99% of the population was white. All subjects gave their informed
consent for inclusion before they participated in the study. The investigations were carried out
following the rules of the Declaration of Helsinki, and the research protocol was approved by the
institutional review board at the University of Wisconsin-Madison. Comparisons between participants
and nonparticipants at each examination have appeared elsewhere [15–20]. In general, those who
participated in a follow-up examination over the 20-year period of the study were more likely to be
younger than nonparticipants who were alive or those who died before follow-up and, with adjustment
for age, were less likely to have early AMD as defined as having severity level 20 or greater on the
5-step Three Continent Consortium AMD severity scale in at least 1 eye [9].
2.2. Procedures
The baseline and follow-up examinations used similar procedures, which have been described in
detail elsewhere [2,4,13,21–27]. Stereoscopic 30° color film fundus photographs centered on the disc
(Diabetic Retinopathy Study standard field 1) and macula (Diabetic Retinopathy Study standard field 2)
and a nonstereoscopic color fundus photograph temporal to but including the fovea of each eye were
obtained. Details of the grading procedure have been described elsewhere [2,4,13,21–27].
2.3. Genetic Measurements
The genetic measurements have been described in detail elsewhere [28]. In brief, samples of DNA
were extracted from buffy coat specimens collected at the baseline examination. The two SNPs most
commonly associated with AMD, Y402H in CFH (rs1061170) and A69S in ARMS2 (rs10490924),
were used in this study. For CFH, T was considered the wild allele and C the risk allele; for ARMS2,
G was considered the wild allele and T the risk allele.
2.4. Definitions
Age was documented at each participant visit and was categorized as <60 years, 60–69 years, or
≥70 years. Body mass index was calculated by dividing a participant’s weight in kilograms by his or
her height in meters squared. Current heavy drinking was defined as the consumption of 4 or more
servings of alcoholic beverages daily at the time of the examination; a serving was defined as 12 fluid
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ounces of beer, 4 fluid ounces of wine, or 1.5 fluid ounces of liquor. Participants were considered
physically active if they engaged in physical activity long enough to work up a sweat at least 3 times
per week. Hypertension was defined as blood pressure ≥140/90 mmHg or use of anti-hypertensive
medication. Aspirin, multivitamin, and anti-hypertensive medication use were determined from self-report.
The severity status of drusen in an eye was defined as follows.











Level 1 (No drusen): No signs of any drusen or of early or late AMD.
Level 2 (Minimal area of small hard distinct drusen): Presence of small hard distinct drusen
<63 µm in diameter as the largest size drusen involving a circular area of the macula of up to
2596 µm² and no other signs of AMD.
Level 3 (Small area of small hard distinct drusen): Presence of small hard distinct drusen
<63 µm in diameter as the largest size drusen involving a circular area of the macula between
2597 µm² and 5192 µm² and no other signs of AMD.
Level 4 (Moderate area of small hard distinct drusen): Presence of small hard distinct
drusen <63 µm in diameter as the largest size drusen involving a circular area of the macula
between 5193 µm² and 9086 µm² and no other signs of AMD.
Level 5 (Large area of small hard distinct drusen): Presence of small hard distinct drusen
<63 µm in diameter as the largest size drusen involving a circular area of the macula greater
than 9086 µm² and no other signs of AMD.
Level 6 (Intermediate drusen): Presence of one or more drusen 63 to 124 µm in diameter as
the largest size drusen and no other signs of AMD.

Early AMD was defined as the presence of small to intermediate drusen, regardless of area of
involvement, with any pigmentary abnormalities (defined as depigmentation and increased retinal pigment)
or the presence of large drusen (≥125 µm in diameter). Late AMD was defined by the presence of
geographic atrophy and signs of exudative AMD, such as serous detachment of the RPE and/or
sensory retina.
2.5. Statistical Analysis
We examined the association of the drusen severity level in an eye and other risk factors measured
at one examination with drusen severity level in that eye at the next examination, 5 years later. Pairs of
visits were accumulated during the 20 years of the study and risk factors were updated for each 5-year
period. Multiple contributions from an individual were accounted for by using generalized estimating
equations (GEE).
An eye was considered at risk for incidence of a specific level on the drusen severity scale if drusen
were gradable at 2 consecutive visits and had a less severe level of drusen at the earlier examination.
The outcome of interest was the development of drusen at or above a given severity level (e.g.,
intermediate drusen or any AMD). For example, development of intermediate drusen (Level 6) was
evaluated for all eyes with Level 1 through Level 5 at the start of an interval. If the severity level was
Level 6 or any AMD at the follow-up visit, the eye was considered to have developed
intermediate drusen.
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Analyses of specific risk factors (age, sex, genotype) were stratified by the initial drusen severity
level. Models were adjusted for age and sex. SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) was
used for all analyses.
3. Results
3.1. Participant Characteristics
There were 3344 individuals who contributed AMD data for at least one pair of consecutive
examinations: 3198 with baseline and five-year follow-up data, 2367 participants with five-year and
10-year follow-up data, 1865 participants with 10-year and 15-year follow-up data, and 1468
participants with 15-year and 20-year follow-up data. For each interval, 75%–80% of individuals had
data available for both eyes, resulting in 15821 total person-eye-visit intervals. Table 1 shows the
characteristics of this group. The percentages of individuals at the start of a five-year follow-up
interval with Level 1, Level 2, Level 3, Level 4, Level 5, and Level 6 were 14%, 26%, 16%, 15%, 14%
and 16%, respectively (Table 1). The genotype distributions for CFH Y402H were 41%, 46% and 13%
for T/T, T/C, and C/C, respectively; the genotype distributions for ARMS2 A69S were 61%, 35%, and
4% for G/G, G/T, and T/T, respectively.
3.2. Incidence of Varying Areas of Small Hard Drusen, Intermediate Drusen, and Any AMD
Figure 1 shows the distribution of drusen severity levels at the follow-up examination for each level
at the start of the interval and Table 2 shows the results of incidence analyses for each drusen severity
level. As severity level at the beginning of an interval increased, so did the development of the more
severe drusen levels (Figure 1). For example, 8% of eyes with Level 1 (n = 2206) at the start of a
five-year follow-up interval developed Level 5 or worse compared with 25% of eyes starting at Level 4
(n = 2370). 49% of eyes with Level 1 (n = 2206) developed Level 2 or worse by the end of a five-year
period, and 36% of eyes with Level 3 (n = 2515) developed Level 4 or worse.
Five-year incidence of Level 6 or worse was 17%, 12%, 10%, 8%, and 7% for individuals with Level 5,
Level 4, Level 3, Level 2, and Level 1 at the start of the interval, respectively. Incidence of any AMD
was higher in eyes with Level 6 at the start of the interval compared to eyes with Level 5 (25% vs. 5%;
odds ratio [OR] = 5.5) and was also higher in eyes with Level 5 vs. Level 4 at the beginning of a
five-year period (OR = 1.8).
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Table 1. Characteristics of individuals included in analyses averaged over all examination
phases in the Beaver Dam Eye Study, 1988–1990 to 2008–2010. ARMS2, age-related
maculopathy susceptibility 2 rs10490924; CFH, complement factor H rs1061170; SD,
standard deviation.
Characteristic
Age, years
Sex

Beginning drusen severity level

CFH genotype

ARMS2 genotype
Hypertension present

Female
Male
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
T/T
T/C
C/C
G/G
G/T
T/T
No
Yes

Body mass index, kg/m²
Smoking history

Heavy drinking history
Physical activity level
Using multivitamins
Currently using aspirin

Never
Past
Current
Never
Past
Current
Active
Sedentary
No
Yes
No
Yes

Person-Eye-Visits (N)
15821
9016
6805
2206
4055
2515
2370
2210
2465
5942
6771
1919
9172
5323
574
7911
7776
15625
7312
6189
2312
13377
2154
276
4843
10969
7720
8101
10946
4854

Mean (SD) or %
62.3 (9.5)
57.0
43.0
13.9
25.6
15.9
15.0
14.0
15.6
40.6
46.3
13.1
60.9
35.3
3.8
50.4
49.6
29.6 (5.6)
46.2
39.1
14.6
84.6
13.6
1.7
30.6
69.4
48.8
51.2
69.3
30.7
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Figure 1. The relationship of no drusen, 4 areas of increasing involvement of the macula
by small hard drusen and intermediate drusen to the 5-year incidence of more severe levels
of drusen and any AMD in the Beaver Dam Eye Study, 1988–1990 to 2008–2010.
3.3. Relationships of Age, Sex and Two AMD Candidate Genes to the Five-Year Incidences of Small
Hard Drusen, Intermediate Drusen and AMD
Figures 2–5 and Supplementary Tables S1–S6 show the relationships between drusen severity level
and AMD status at follow-up by age, sex and genetic information, stratified by initial drusen level.
Figure 2 shows the distribution of the follow-up drusen severity level and AMD status by age group.
Odds ratios for these relationships are presented in Supplementary Tables S1–S6, with each possible
outcome in a separate table. Older age was associated with higher five-year incidence of most
outcomes and the associations were stronger in eyes with larger areas of small hard drusen and more
severe lesions. Sex was not associated with the development of any drusen outcome (Figure 3).
Figures 4 and 5 and Supplementary Tables S1–S6 show the relationships of the CFH and ARMS2
candidate genes stratified by drusen severity levels at the beginning of an interval to the five-year
incidences for each drusen severity level and AMD outcome. While few individuals had two risk
alleles, especially for ARMS2, the increasing incidence was still apparent and statistically significant
for some relationships. For CFH Y402H genotype (Figure 3), the strongest associations for incidence
of Level 6 (Supplementary Table S5) and incidence of any AMD (Supplementary Table S6) occurred
when the initial severity was at least Level 4. Incidence of Level 6 was about 9%–10% regardless of
the number of risk alleles for CFH Y402H (p = 0.35 for any differences after adjusting for age and sex)
when initial drusen severity was Level 3 but ranged from 14% to 25% for 0 vs. 2 risk alleles when the
initial severity was Level 5 (OR = 1.4 per risk allele, p < 0.001 after adjusting for age and sex). Where
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an association with CFH was present, the association was stronger in individuals with 2 risk alleles
compared to individuals with only one risk allele.
Table 2. Incidence of specific level of drusen area/severity by initial severity level. N is the
number of person-visit-eyes at risk. The p value is the Wald test for any differences
between levels. AMD, age-related macular degeneration; CI, confidence interval; OR,
odds ratio.
Incidence of
Level 2 or worse
Level 3 or worse

Level 4 or worse

Level 5 or worse

Level 6 or worse

Any AMD

Beginning
Level
Level 1
Level 1
Level 2
Level 1
Level 2
Level 3
Level 1
Level 2
Level 3
Level 4
Level 1
Level 2
Level 3
Level 4
Level 5
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6

N at Risk

% Incident

2206
2206
4055
2206
4055
2515

48.9
22.8
37.8
14.3
22.5
35.5

2206
4055
2515
2370
2206
4055
2515
2370
2210
2206
4055
2515
2370
2210
2465

7.9
11.3
18.5
24.5
6.8
7.7
9.8
11.6
17.3
3.1
2.5
3.1
2.9
5.1
25.2

Comparison
Level

OR (95% CI)

p Value
<0.001

Level 1

2.0 (1.8, 2.3)
<0.001

Level 1
Level 2
Per level

1.7 (1.5, 1.9)
1.9 (1.7, 2.1)
1.8 (1.7, 1.9)

Level 1
Level 2
Level 3
Per level

1.4 (1.2, 1.7)
1.7 (1.5, 2.0)
1.4 (1.2, 1.6)
1.5 (1.5, 1.6)

Level 1
Level 2
Level 3
Level 4
Per level

1.2 (1.0, 1.4)
1.3 (1.1, 1.5)
1.2 (1.0, 1.4)
1.5 (1.3, 1.8)
1.3 (1.2, 1.4)

Level 1
Level 2
Level 3
Level 4
Level 5
Per level

0.8 (0.6, 1.1)
1.2 (0.9, 1.6)
0.9 (0.7, 1.3)
1.8 (1.3, 2.4)
5.5 (4.5, 6.8)
1.8 (1.7, 1.9)

<0.001
<0.001

<0.001
<0.001

<0.001
<0.001

<0.001
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Figure 2. Five-year incidence of increasing area of small hard drusen, intermediate drusen,
and any AMD by age group (<60, 60–69, and ≥70 years) and severity level at the
beginning of the interval.
For ARMS2 A69S genotype (Figure 4), most of the strongest associations were for smaller areas of
drusen at the start of an interval. Having two risk alleles was more strongly associated with incidence
than having one risk allele present. For example, incidence of Level 6 was higher when there were two
risk alleles compared to one or 0, but was only statistically significant when the initial level of drusen
severity was Level 1, 2, or 3. Among individuals with Level 1, 13% of those with the T/T genotype
(2 risk alleles), 8% of the G/T (1 risk allele) and 6% of those with G/G (0 risk alleles) developed Level
6 over the next five years (OR = 1.7 per risk allele, p = 0.002 after adjusting for age and sex). Among
persons with Level 5, 17%, 17% and 23% of those with 0, 1 and 2 risk alleles, respectively, developed
Level 6 (OR = 1.2 per risk allele, p = 0.16 after adjusting for age and sex).
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Figure 3. Five-year incidence of increasing area of small hard drusen, intermediate drusen,
and any AMD by sex and severity level at the beginning of the interval. F = female;
M = male.

Figure 4. Five-year incidence of increasing area of small hard drusen, intermediate drusen,
and any AMD by CFH Y402H (rs1061170) genotype and severity level at the beginning of
the interval.
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Figure 5. Five-year incidence of increasing area of small hard drusen, intermediate drusen,
and any AMD by ARMS2 A69S (rs10490924) genotype and severity level at the beginning
of the interval.
4. Discussion
There is a general consensus that large soft drusen and pigmentary abnormalities define an early
AMD phenotype and that neovascular AMD and pure geographic atrophy define the late advanced
AMD phenotype. However, there is less agreement regarding whether a large area of small hard
distinct drusen defines an even earlier AMD phenotype. In the Beaver Dam Eye Study, we found that
the incidence of increasingly larger areas of small hard drusen (more severe level) is dependent upon
the prior less severe level (smaller area) of small hard drusen. Even an eye with a minimal area of small
hard drusen (Level 2) has approximately 50% greater odds of progressing by one step than an eye with
no drusen (Level 1). While there is some variability, a stepwise increase in severity seems reasonable
to assume. Furthermore, the data are consistent with the notion that there is an increasing likelihood of
progression to intermediate drusen or any AMD with a larger area of small hard drusen. We had
previously reported that a large area >9086 µm²) of small hard distinct drusen compared to a small area
(≤2596 µm²) of involvement of these drusen in the absence of any other signs of AMD was associated
with increased 15-year cumulative incidence of early AMD (18% vs. 5%) and late AMD (1.5% vs.
0.4%) [7]. This was consistent with earlier observations from clinical studies suggesting that eyes with
large numbers of small hard drusen were at greater risk of developing AMD [29–31].
The process by which large soft drusen develop and their relation to small hard drusen is poorly
understood [29,31–33]. Large soft drusen have been thought to result either from the aggregation of
small hard drusen or in areas where small hard drusen appear to be absent. Hard and soft drusen have
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differing molecular components. Sarks et al. and others [14,34,35] have described the focal
aggregation of small hard drusen into mounds of membranous debris, which accumulate as a
widespread shallow layer between the basement membrane of the pigment epithelium and Bruch
membrane. Small subclinical sized drusen (<30 µm in diameter) not usually visible on
ophthalmoscopy have been found to become confluent and form soft drusen [31]. Areas surrounding
individual large soft drusen have been shown to contain several small merging drusen and thick basal
laminar drusen. Further understanding of the biochemical, physiological, and anatomic changes that
take place as large soft drusen evolve is needed.
We wanted to examine whether age and different high risk AMD candidate genes might affect
different stages of drusen development in addition to the natural history of drusen development. In the
Beaver Dam Eye Study, genetic associations from CFH Y402H and ARMS2 A69S appear to affect
different stages of drusen development. Some of these differences are related to underpowered tests
with ARMS2 but may also represent differences in the genetic influences on disease.
In the present report, besides the differing associations of the SNPs of two genes associated with
AMD (CFH Y402H rs1061190 and ARMS2 A69S rs10490924), we found relationships of age but not
sex to the incidence of increasing areas of macular involvement with small hard drusen, intermediate
drusen, and AMD. It is difficult to compare our findings with those of other population-based studies
that have examined the incidence and progression of small hard distinct drusen due to differences in
the criteria defining the drusen endpoint among the studies. In the Inter99 Eye Study [36], there was no
relationship between the presence of 20 or more small hard macular drusen with gene SNPs CFH
Y402H, LOC387715 A69S, HTRA1 rs11200638, CFB R32Q, and CFB L9H while drusen >63 µm in
diameter were related to CFH Y402H. The Münster Aging and Retina Study (MARS) [37] examined
drusen features such as number, confluence, type, size, and area occupied by macular drusen in 406
patients with early AMD and 170 healthy controls with a follow-up examination after 2.6 years. In that
study, over a 2½ year period, CFH Y402H but not ARMS2 A69S was associated with the development
of 20 or more small hard drusen in eyes described as healthy at baseline. In another study, investigators
developing a new clinical classification system for AMD concluded that small drusen (<63 µm) should
be considered to be a result of normal aging changes and that there was no clinically relevant increased
risk of late AMD developing in these eyes [30]. In that study, persons with intermediate drusen (63 to
124 µm in diameter) were considered to have early AMD. These findings from the Beaver Dam Eye
Study and other studies suggest that intermediate drusen may be one of the earliest stages of AMD
clinically identifiable by grading of fundus photographs. Others have shown an increased risk of
developing AMD when intermediate drusen are present [30,36,37].
Our study has many strengths, including repeated examinations during a 20-year period that used
detailed standardized procedures for obtaining stereoscopic color fundus photographs of the macula
and an objective system for grading those photographs for AMD phenotypes. However, the study also
had a number of limitations. First, the Beaver Dam Eye Study cohort is racially/ethnically
homogeneous (over 99% white), which limits our inferences regarding these findings in nonwhites.
Second, we used SNPs from only two AMD candidate genes; it is possible that inclusion of all the
identified possible loci may have affected our findings. Non-AMD related processes may cause the
development of the first few small hard macular drusen. There may also be more misclassification in
eyes with no or only small drusen because it is more difficult to detect some small hard drusen, leading
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to greater variability in grading their presence than in eyes with larger drusen or more severe late signs
of AMD and resulting in detection bias due to size. Mortality may also have limited the interpretation
of associations because of selective survival.
5. Conclusions
This report provides long-term population-based observations regarding the relationships of age,
sex, and presence of risk alleles for two AMD candidate genes, CFH Y402H rs1061170 and ARMS2
A69S rs10490924, to the incidence of small hard drusen, as well as their role in the natural history of
AMD in its earliest clinical stages using grading of stereoscopic 30° color fundus film photography.
The findings from the Beaver Dam Eye Study and others provide some evidence that intermediate
drusen and large areas of small hard drusen may be early clinically detectable stages in the trajectory
of the disease and not just risk indicators. Intervals of observation of the cohort longer than five years
may be needed to provide enough time to evaluate the natural history of no or a few small drusen
progressing to AMD. This will be evaluated by multistate modeling in future analyses. Our findings
also suggest the genetic risks from CFH and ARMS2 may influence different stages of the disease in
different ways. Inclusion of newer technological assessment tools such as spectral domain optical
coherence tomography and autofluorescence may provide more sensitive and reliable approaches to
detect and quantitate even earlier stages of AMD [33]. This may prove useful in the study of
pathogenetic risk factors only associated with these earlier stages of AMD. However, risks and benefits
of defining an individual as having early AMD when newer classifications are used in clinical practice
will need to be examined further.
Acknowledgments
This study was supported by National Institutes of Health grant EY06594 (Barbara E. K. Klein and
Ronald Klein) and, in part, by Research to Prevent Blindness, New York, NY. No funds were received
for covering the costs to publish in open access. The funding sponsors had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the
decision to publish results. The content is solely the responsibility of the authors and does not
necessarily reflect the official views of the National Eye Institute or the National Institutes of Health.
The authors acknowledge Heidi M. G. Christian, and Erin L. Syth, for technical assistance and
editing of the manuscript.
Author Contributions
Ronald Klein conceived and designed the analysis. Ronald Klein, Barbara E. K. Klein, Theru A.
Sivakumaran and Sudha K. Iyengar performed data collection. Chelsea E. Myers and Kristine E. Lee
analyzed the data. Ronald Gangnon contributed analysis tools and statistical advice. Ronald Klein
wrote the initial manuscript draft. All authors contributed to critical review and revision of the
manuscript draft.

J. Clin. Med. 2015, 4

438

Conflicts of Interest
The authors declare no conflict of interest.
References
1.

2.

3.
4.
5.

6.

7.

8.
9.

10.

11.

12.
13.

Van der Schaft, T.L.; Mooy, C.M.; de Bruijn, W.C.; Oron, F.G.; Mulder, P.G.; de Jong, P.T.
Histologic features of the early stages of age-related macular degeneration. A statistical analysis.
Ophthalmology 1992, 99, 278–286.
Ferris, F.L.; Davis, M.D.; Clemons, T.E.; Lee, L.Y.; Chew, E.Y.; Lindblad, A.S.; Milton, R.C.;
Bressler, S.B.; Klein, R. A simplified severity scale for age-related macular degeneration: AREDS
Report No. 18. Arch. Ophthalmol. 2005, 123, 1570–1574.
Klein, R.; Klein, B.E.; Jensen, S.C.; Meuer, S.M. The five-year incidence and progression of
age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 1997, 104, 7–21.
Seddon, J.M. Genetic and environmental underpinnings to age-related ocular diseases.
Investig. Ophthalmol. Vis. Sci. 2013, 54, ORSF28–ORSF30; doi:10.1167/iovs.13-13234.
Buitendijk, G.H.; Rochtchina, E.; Myers, C.; van Duijn, C.M.; Lee, K.E.; Klein, B.E.;
Meuer, S.M.; de Jong, P.T.; Holliday, E.G.; Tan, A.G.; et al. Prediction of age-related macular
degeneration in the general population: The Three Continent AMD Consortium. Ophthalmology
2013, 120, 2644–2655.
Klein, M.L.; Ferris, F.L., III; Francis, P.J.; Lindblad, A.S.; Chew, E.Y.; Hamon, S.C.; Ott, J.
Progression of geographic atrophy and genotype in age-related macular degeneration.
Ophthalmology 2010, 117, 1554–1559.
Klein, R.; Klein, B.E.; Knudtson, M.D.; Meuer, S.M.; Swift, M.; Gangnon, R.E. Fifteen-year
cumulative incidence of age-related macular degeneration: The Beaver Dam Eye Study.
Ophthalmology 2007, 114, 253–262.
Mitchell, P.; Wang, J.J.; Foran, S.; Smith, W. Five-year incidence of age-related maculopathy
lesions: The Blue Mountains Eye Study. Ophthalmology 2002, 109, 1092–1097.
Klein, R.; Meuer, S.M.; Myers, C.E.; Buitendijk, G.H.; Rochtchina, E.; Choudhury, F.;
de Jong, P.T.; McKean-Cowdin, R.; Iyengar, S.K.; Gao, X.; et al. Harmonizing the classification
of age-related macular degeneration in the Three Continent AMD consortium. Ophthalmic
Epidemiol. 2014, 21, 14–23.
Klaver, C.C.; Assink, J.J.; van, L.R.; Wolfs, R.C.; Vingerling, J.R.; Stijnen, T.; Hofman, A.;
de Jong, P.T. Incidence and progression rates of age-related maculopathy: The Rotterdam Study.
Investig. Ophthalmol. Vis. Sci. 2001, 42, 2237–2241.
Davis, M.D.; Gangnon, R.E.; Lee, L.Y.; Hubbard, L.D.; Klein, B.E.; Klein, R.; Ferris, F.L.;
Bressler, S.B.; Milton, R.C. The Age-Related Eye Disease Study severity scale for age-related
macular degeneration: AREDS Report No. 17. Arch. Ophthalmol. 2005, 123, 1484–1498.
Seddon, J.M.; Sharma, S.; Adelman, R.A. Evaluation of the clinical age-related maculopathy
staging system. Ophthalmology 2006, 113, 260–266.
Klein, R.; Klein, B.E.; Linton, K.L. Prevalence of age-related maculopathy. The Beaver Dam Eye
Study. Ophthalmology 1992, 99, 933–943.

J. Clin. Med. 2015, 4

439

14. Gass, J.D. Drusen and disciform macular detachment and degeneration. Arch. Ophthalmol. 1973,
90, 206–217.
15. Klein, R.; Klein, B.E.; Lee, K.E.; Cruickshanks, K.J.; Chappell, R.J. Changes in visual acuity in
a population over a 10-year period: The Beaver Dam Eye Study. Ophthalmology 2001, 108,
1757–1766.
16. Klein, R.; Klein, B.E.; Lee, K.E.; Cruickshanks, K.J.; Gangnon, R.E. Changes in visual acuity in a
population over a 15-year period: The Beaver Dam Eye Study. Am. J. Ophthalmol. 2006, 142,
539–549.
17. Klein, R.; Klein, B.E.; Lee, K.E. Changes in visual acuity in a population. The Beaver Dam Eye
Study. Ophthalmology 1996, 103, 1169–1178.
18. Klein, R.; Lee, K.E.; Gangnon, R.E.; Klein, B.E. Incidence of visual impairment over a 20-year
period: The Beaver Dam Eye Study. Ophthalmology 2013, 120, 1210–1219.
19. Klein, R.; Klein, B.E.; Linton, K.L.; de Mets, D.L. The Beaver Dam Eye Study: Visual acuity.
Ophthalmology 1991, 98, 1310–1315.
20. Linton, K.L.; Klein, B.E.; Klein, R. The validity of self-reported and surrogate-reported cataract
and age-related macular degeneration in the Beaver Dam Eye Study. Am. J. Epidemiol. 1991, 134,
1438–1446.
21. Klein, R.; Klein, B.E.; Tomany, S.C.; Meuer, S.M.; Huang, G.H. Ten-year incidence and
progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology 2002, 109,
1767–1779.
22. Klein, R.; Klein, B.E. The Beaver Dam Eye Study II. Manual of Operations. National Technical
Information Sevice: Springfield, Virginia, USA, 1995. Accession No. PB95-273827.
23. Klein, R.; Klein, B.E. The Beaver Dam Eye Study III. Manual of Operations. National Technical
Information Service: Springfield, Virginia, USA, 1999. Accession No. PB99-137861.
24. Klein, B.E.; Klein, R. The Beaver Dam Eye Study V. Manual of Operations. National Technical
Information Sevice: Springfield, Virginia, USA, 2010. Accession No. PB2010-114194.
25. Klein, R.; Klein, B.E. The Beaver Dam Eye Study. Manual of Operations, Revised. National
Technical Information Sevice: Springfield, Virginia, USA, 1991. Accession No. PB91-149823.
26. Klein, R.; Davis, M.D.; Magli, Y.L.; Segal, P.; Klein, B.E.; Hubbard, L. The Wisconsin
Age-Related Maculopathy Grading System. Ophthalmology 1991, 98, 1128–1134.
27. Klein, R.; Davis, M.D.; Magli, Y.L.; Segal, P.; Klein, B.E.; Hubbard, L. The Wisconsin
Age-Related Maculopathy Grading System. National Technical Information Sevice: Springfield,
Virginia, USA, 1991. Accession No. PB91-184267.
28. Klein, R.; Myers, C.E.; Meuer, S.M.; Gangnon, R.E.; Sivakumaran, T.A.; Iyengar, S.K.; Lee, K.E.;
Klein, B.E. Risk alleles in CFH and ARMS2 and the long-term natural history of age-related
macular degeneration: The Beaver Dam Eye Study. JAMA Ophthalmol. 2013, 131, 383–392.
29. Ardeljan, D.; Chan, C.C. Aging is not a disease: Distinguishing age-related macular degeneration
from aging. Prog. Retin. Eye Res. 2013, 37, 68–89.
30. Ferris, F.L., III; Wilkinson, C.P.; Bird, A.; Chakravarthy, U.; Chew, E.; Csaky, K.; Sadda, S.R.
Clinical classification of age-related macular degeneration. Ophthalmology 2013, 120, 844–851.

J. Clin. Med. 2015, 4

440

31. Rudolf, M.; Seckerdieck, K.; Grisanti, S.; Curcio, C.A. Internal structure consistent with
remodelling in very small drusen, revealed by filipin histochemistry for esterified cholesterol. Br.
J. Ophthalmol. 2014, 98, 698–702.
32. Rudolf, M.; Clark, M.E.; Chimento, M.F.; Li, C.M.; Medeiros, N.E.; Curcio, C.A. Prevalence and
morphology of druse types in the macula and periphery of eyes with age-related maculopathy.
Investig. Ophthalmol. Vis. Sci. 2008, 49, 1200–1209.
33. Yehoshua, Z.; Wang, F.; Rosenfeld, P.J.; Penha, F.M.; Feuer, W.J.; Gregori, G. Natural history of
drusen morphology in age-related macular degeneration using spectral domain optical coherence
tomography. Ophthalmology 2011, 118, 2434–2441.
34. Gragoudas, E.S.; Chandra, S.R.; Friedman, E.; Klein, M.L.; Van, B.M. Disciform degeneration of
the macula. II. Pathogenesis. Arch. Ophthalmol. 1976, 94, 755–757.
35. Sarks, S.H.; Van, D.D.; Maxwell, L.; Killingsworth, M. Softening of drusen and subretinal
neovascularization. Trans. Ophthalmol. Soc. UK 1980, 100, 414–422.
36. Munch, I.C.; Ek, J.; Kessel, L.; Sander, B.; Almind, G.J.; Brondum-Nielsen, K.; Linneberg, A.;
Larsen, M. Small, hard macular drusen and peripheral drusen: Associations with AMD genotypes
in the Inter99 Eye Study. Investig. Ophthalmol. Vis. Sci. 2010, 51, 2317–2321.
37. Dietzel, M.; Pauleikhoff, D.; Arning, A.; Heimes, B.; Lommatzsch, A.; Stoll, M.; Hense, H.W.
The contribution of genetic factors to phenotype and progression of drusen in early age-related
macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol. 2014, 252, 1273–1281.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).

